Adaptimmune is a medium sized innovative biotech with just under 300 employees in the UK and over 150 in the US. We want to transform the lives of people with cancer by designing and delivering cell therapies. We conduct clinical trials with our three SPEAR T-cell therapies (afamitresgene autoleucel, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. We have reported responses in our ongoing trials in patients with 6 different solid tumors, including synovial sarcoma, melanoma, head and neck, lung, gastroesophageal, and liver cancers. We aim to file our first BLA in 2022, for people with synovial sarcoma.
Our unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells so that our therapies can harness the body's own immune system to find and destroy diseased cells. In addition to our three late-stage products, we have a strong pipeline of other cell therapies, which we intend to take to the clinic as soon as possible.